162 related articles for article (PubMed ID: 9822548)
21. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
[TBL] [Abstract][Full Text] [Related]
22. Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.
Yamaotsu N; Fujii H; Nagase H; Hirono S
Bioorg Med Chem; 2010 Jun; 18(12):4446-52. PubMed ID: 20478711
[TBL] [Abstract][Full Text] [Related]
23. Establishment of kappa opioid receptor agonists pharmacophore with molecular modeling method.
Liu DX; Tang Y; Jiang HL; Chen KX; Ji RY
Zhongguo Yao Li Xue Bao; 1998 Sep; 19(5):445-50. PubMed ID: 10375807
[TBL] [Abstract][Full Text] [Related]
24. 2D conformationally sampled pharmacophore: a ligand-based pharmacophore to differentiate delta opioid agonists from antagonists.
Bernard D; Coop A; MacKerell AD
J Am Chem Soc; 2003 Mar; 125(10):3101-7. PubMed ID: 12617677
[TBL] [Abstract][Full Text] [Related]
25. Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.
Zhang Y; Sham YY; Rajamani R; Gao J; Portoghese PS
Chembiochem; 2005 May; 6(5):853-9. PubMed ID: 15776407
[TBL] [Abstract][Full Text] [Related]
26. Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
Le Bourdonnec B; Ajello CW; Seida PR; Susnow RG; Cassel JA; Belanger S; Stabley GJ; DeHaven RN; DeHaven-Hudkins DL; Dolle RE
Bioorg Med Chem Lett; 2005 May; 15(10):2647-52. PubMed ID: 15863335
[TBL] [Abstract][Full Text] [Related]
27. Fully automated flexible docking of ligands into flexible synthetic receptors using forward and inverse docking strategies.
Kämper A; Apostolakis J; Rarey M; Marian CM; Lengauer T
J Chem Inf Model; 2006; 46(2):903-11. PubMed ID: 16563022
[TBL] [Abstract][Full Text] [Related]
28. Rapid protein-ligand docking using soft modes from molecular dynamics simulations to account for protein deformability: binding of FK506 to FKBP.
Zacharias M
Proteins; 2004 Mar; 54(4):759-67. PubMed ID: 14997571
[TBL] [Abstract][Full Text] [Related]
29. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions.
Lu SY; Jiang YJ; Lv J; Wu TX; Yu QS; Zhu WL
J Mol Graph Model; 2010 Jun; 28(8):766-74. PubMed ID: 20227312
[TBL] [Abstract][Full Text] [Related]
30. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
Axe FU; Bembenek SD; Szalma S
J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444
[TBL] [Abstract][Full Text] [Related]
31. Probing the function, conformational plasticity, and dimer-dimer contacts of the GluR2 ligand-binding core: studies of 5-substituted willardiines and GluR2 S1S2 in the crystal.
Jin R; Gouaux E
Biochemistry; 2003 May; 42(18):5201-13. PubMed ID: 12731861
[TBL] [Abstract][Full Text] [Related]
32. Computational study of antagonist/alpha1A adrenoceptor complexes--observations of conformational variations on the formation of ligand/receptor complexes.
Kinsella GK; Rozas I; Watson GW
J Med Chem; 2006 Jan; 49(2):501-10. PubMed ID: 16420037
[TBL] [Abstract][Full Text] [Related]
33. Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists.
Ivanov AA; Baskin II; Palyulin VA; Piccagli L; Baraldi PG; Zefirov NS
J Med Chem; 2005 Nov; 48(22):6813-20. PubMed ID: 16250640
[TBL] [Abstract][Full Text] [Related]
34. kappa-Opioid activity of the four stereoisomers of the peripherally selective kappa-agonists, EMD 60,400 and EMD 61,753.
Gottschlich R; Krug M; Barber A; Devant RM
Chirality; 1994; 6(8):685-9. PubMed ID: 7857777
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
36. Subtype selectivity and flexibility of ionotropic glutamate receptors upon antagonist ligand binding.
Pentikäinen U; Settimo L; Johnson MS; Pentikäinen OT
Org Biomol Chem; 2006 Mar; 4(6):1058-70. PubMed ID: 16525550
[TBL] [Abstract][Full Text] [Related]
37. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
38. Recognition of privileged structures by G-protein coupled receptors.
Bondensgaard K; Ankersen M; Thøgersen H; Hansen BS; Wulff BS; Bywater RP
J Med Chem; 2004 Feb; 47(4):888-99. PubMed ID: 14761190
[TBL] [Abstract][Full Text] [Related]
39. Molecular recognition of opioid receptor ligands.
Kane BE; Svensson B; Ferguson DM
AAPS J; 2006 Mar; 8(1):E126-37. PubMed ID: 16584119
[TBL] [Abstract][Full Text] [Related]
40. NMR and structural model of dynorphin A (1-17) bound to dodecylphosphocholine micelles.
Tessmer MR; Kallick DA
Biochemistry; 1997 Feb; 36(8):1971-81. PubMed ID: 9047294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
